Moderna Inc. ($MRNA) Stock Forecast: Down 5.4% Today

What is Moderna Inc.?

Moderna (MRNA) is a leading biotechnology company known for its innovative mRNA technology, particularly in the development of vaccines and therapeutics. The stock is a key player in the healthcare sector and is closely watched by investors for its groundbreaking advancements in medical science.

Why is Moderna Inc. going down?

MRNA stock is down 5.4% on Dec 31, 2025 19:40

• Moderna's stock experienced a bearish movement, closing down 2.38% in the recent trading session, underperforming the broader market indices.
• The significant layoffs in the biotech industry, including at Moderna, may have contributed to investor concerns about the company's future growth prospects.
• Despite the recent dip, Moderna has shown strong performance over the past month, outpacing the Medical sector, indicating potential volatility in response to market news and events.
• The upcoming Investor Event – Analyst Day hosted by Moderna could provide insights into the company's strategic direction, potentially impacting investor sentiment and stock movement in the near future.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

BioAtla secures $40 million for phase 3 cancer drug development

BioAtla, Inc. has secured $40 million through a special purpose vehicle transaction with GATC Health Corp. to fund the Phase 3 clinical trials of its cancer drug, ozuriftamab vedotin (Oz-V). The biopharmaceutical company will receive an initial $5 million, with the remaining $35 million closing in Q1 2026, and will retain 65% ownership of Oz-V across solid tumor indications. The Phase 3 trial for OPSCC is expected to begin in early 2026, building on Oz-V's Fast Track Designation from the FDA.

https://www.investing.com/news/company-news/bioatla-secures-40-million-for-phase-3-cancer-drug-development-93CH-4426422

More than 4,600 Massachusetts biotech workers lost jobs in 2025 as industry contracts

In 2025, over 4,600 biotech workers in Massachusetts faced job losses as the industry contracted, with companies like Moderna and Sarepta leading the layoffs. This article provides a list of the companies affected and highlights the significant impact on the state's life sciences sector. The piece previews a detailed report on these layoffs within the Massachusetts life sciences industry.

https://www.bizjournals.com/boston/news/2025/12/31/boston-biotech-2025-layoffs.html

BioRestorative Therapies (OTCMKTS:BRTXQ) Stock Price Down 1.8% - Should You Sell?

BioRestorative Therapies (OTCMKTS:BRTXQ) saw its stock price decline by 1.8% on Tuesday, trading at $1.10 with significantly reduced volume compared to its daily average. The company, a clinical-stage regenerative medicine firm, is valued at $1.80 billion, has a negative P/E ratio, and the stock is trading below its 50-day and 200-day moving averages.

https://www.marketbeat.com/instant-alerts/biorestorative-therapies-otcmktsbrtxq-stock-price-down-18-should-you-sell-2025-12-30/

Moderna (MRNA) Falls More Steeply Than Broader Market: What Investors Need to Know

Moderna (MRNA) closed down 2.38% in a recent trading session, underperforming the broader S&P 500, Dow, and Nasdaq markets. Despite this daily dip, the stock gained 28.93% over the past month, significantly outpacing the Medical sector. Analysts predict an EPS of -$2.79 and revenue of $683.27 million for its upcoming earnings release.

https://www.sharewise.com/de/news_articles/Moderna_MRNA_Falls_More_Steeply_Than_Broader_Market_What_Investors_Need_to_Know_Zacks_20251230_2345

Moderna to Host Investor Event – Analyst Day

Moderna, Inc. announced it will host an Investor Event – Analyst Day on Thursday, November 20, 2025, at 9:00 a.m. ET. The event will feature presentations from management detailing Moderna's development and commercial strategy and key business considerations. A live webcast and subsequent replay will be available on Moderna's investor website.

https://www.vcstar.com/press-release/story/8917/moderna-to-host-investor-event-analyst-day/

Trending Today

Shiba Inu ($SHIB) Crypto Forecast: Up 5.2% Today

Ethena ($ENA) Crypto Forecast: Up 5.1% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.0% Today

Pepe ($PEPE) Crypto Forecast: Up 6.2% Today

Chiliz ($CHZ) Crypto Forecast: Up 5.3% Today

Republic Services Inc. ($RSG) Stock Forecast: Down 1.3% Today

Moderna Inc. Price History

05.11.2025 - MRNA Stock was up 7.9%

• Moderna's stock experienced a surge today after a significant study from France verified the safety and effectiveness of its COVID-19 vaccine, reassuring investors about the company's primary product.
• This upward momentum was also backed by the company surpassing its 20-day moving average, indicating a short-term uptrend and optimistic earnings estimate adjustments.
• Institutional engagement with Moderna showed a mixed picture, with one entity reducing its position notably, while another entity acquired a considerable number of shares in the second quarter.
• Overall, the encouraging developments concerning the COVID-19 vaccine efficacy and technical signals played a role in the strong bullish movement witnessed in Moderna's stock today.

05.11.2025 - MRNA Stock was up 6.3%

• Moderna's positive market movement is linked to its surpassing of the 20-day moving average, indicating a favorable short-term trend and capturing the attention of traders.
• While a decrease in the stake held by Skandinaviska Enskilda Banken AB publ initially raised some concerns, the sizeable acquisition of shares by Norges Bank, alongside optimistic earnings forecast adjustments, likely bolstered investor trust in the stock.
• Despite a year-over-year revenue decline, Moderna's quarterly earnings surpassing expectations might have reassured investors regarding the company's growth prospects, playing a role in the current market positivity.
• In summary, Moderna's stock appears to have been driven upwards today by a blend of technical strength, encouraging earnings projections, and institutional investments.

31.11.2025 - MRNA Stock was down 5.4%

• Moderna's stock experienced a bearish movement, closing down 2.38% in the recent trading session, underperforming the broader market indices.
• The significant layoffs in the biotech industry, including at Moderna, may have contributed to investor concerns about the company's future growth prospects.
• Despite the recent dip, Moderna has shown strong performance over the past month, outpacing the Medical sector, indicating potential volatility in response to market news and events.
• The upcoming Investor Event – Analyst Day hosted by Moderna could provide insights into the company's strategic direction, potentially impacting investor sentiment and stock movement in the near future.

17.11.2025 - MRNA Stock was up 5.5%

• Moderna's bullish movement can be attributed to its participation in the prestigious J.P. Morgan Healthcare Conference, where it showcased its advancements in mRNA technology and its commitment to making a positive impact.
• The positive news of the CHMP backing EU approval for Moderna's new COVID-19 vaccine, mNexspike, for individuals aged 12 and older, also contributed to the stock's upward momentum.
• Despite Pfizer's disappointing revenue outlook affecting its stock and dragging down shares of vaccine rivals like Moderna, the overall market sentiment towards Moderna seems to have been buoyed by its continuous innovation and progress in developing new vaccines and therapies.
• Moderna's announcement of dosing the first patient in a Phase 1/2 study of an investigational T-cell engager for multiple myeloma further showcased the company's diversification and expansion into new treatment areas, adding to investor optimism.

11.10.2025 - MRNA Stock was up 5.0%

• The company recorded a third-quarter loss that was notably under projections, signaling a solid financial performance.
• Moderna's quarterly sales surpassed estimates, highlighting its robust revenue generation.
• The favorable outcomes in earnings and revenue suggest a promising financial trajectory for Moderna, potentially bolstering investor confidence and fueling the upward trend in its stock price.
• The revised sales forecast, coupled with the exceptional financial results, likely played a significant role in driving Moderna's stock price upward today.

18.11.2025 - MRNA Stock was up 5.1%

• Moderna's stock surged as a French study confirmed the effectiveness of its COVID-19 vaccine, showcasing a significant reduction in COVID-19 deaths among vaccinated individuals.
• The anticipation surrounding Moderna's presentation at the J.P. Morgan Healthcare Conference also contributed to the bullish momentum, highlighting the company's continued advancements in the healthcare sector.
• The broader biotech sector's positive performance, driven by successful clinical data, new drug launches, and increased M&A activity, further boosted Moderna's stock price.
• Despite facing some analyst skepticism and insider selling, Moderna's stock managed to outperform, showcasing investor confidence in the company's growth prospects and its position in the biotech industry.

23.11.2025 - MRNA Stock was down 8.8%

• Moderna CEO's decision to retain expiring stock options and show confidence in the company's recovery may have unsettled investors, contributing to the bearish movement.
• Increased stake by prominent institutional investors such as Thrivent Financial for Lutherans could signal faith in Moderna's future, but a director selling a large number of shares might have alarmed other investors.
• The funding from CEPI for a Phase 3 trial of Moderna's mRNA pandemic influenza vaccine candidate might have been overshadowed by short-term worries, impacting the stock price negatively.
• While the positive news regarding Biogen's sustained benefits for ALS patients did not have a direct influence on Moderna, it could have shifted attention and investments away from Moderna, leading to a decline in its stock performance.

23.11.2025 - MRNA Stock was down 5.0%

• Institutional investor, Thrivent Financial for Lutherans, notably increased its stake in Moderna by 600.7% in the second quarter, signaling strong institutional interest. However, concerns arose among investors due to a director selling a substantial number of shares, potentially contributing to the bearish movement.
• There are positive signs for Moderna's pipeline with the news of CEPI funding a pivotal Phase 3 trial for the company's mRNA pandemic influenza vaccine candidate. Despite this, profit-taking and worries about market saturation for vaccines could be influencing market activity.
• GSK PLC's positive quarterly earnings and guidance may have diverted investor attention from Moderna, impacting MRNA's stock performance negatively.
• The absence of specific adverse developments related to Moderna suggests that the market's bearish movement may stem from broader market sentiment or sector rotation rather than company-specific factors.

19.11.2025 - MRNA Stock was up 5.0%

• Moderna's bullish movement today could be attributed to the positive investor sentiment following its participation in the 44th Annual J.P. Morgan Healthcare Conference, where it showcased its developments in mRNA medicine.
• The news of receiving funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for its bird flu vaccine candidate might have also boosted investor confidence in Moderna's future prospects.
• Despite the muted revenues and growth concerns, the market seems to be focusing on the potential of Moderna's innovative approach to vaccine development, driving the bullish movement in the stock today.

20.10.2025 - MRNA Stock was down 5.2%

• Moderna stock saw a decrease in value after two notable revelations concerning its finances and business strategy.
• Market sentiment towards the company may have turned pessimistic, reflecting potential apprehensions regarding its future financial trajectory and strategic decisions.
• Investors could be adopting a watchful stance on Moderna until further details emerge on the implications of these announcements for the company's expansion opportunities.

24.11.2025 - MRNA Stock was down 5.7%

• Moderna’s stock saw a decline to approximately $32.29 after a surge in late December. Several factors contributed to this movement:
• Investor worries regarding bird flu funding from CEPI and the progress of Moderna's mNEXSPIKE vaccine evaluated by the European Medicines Agency.
• Scrutiny on the company's financial moves, which include securing a $1.5 billion loan and outlining 2026 growth targets.
• Analysts have an overall "Hold" consensus rating with an average 12-month target price of $33.25, reflecting a cautious stance on the stock.
• The recent uptick in Moderna’s stock was primarily due to enhanced liquidity and cost containment rather than fundamental business growth, leading some investors to sell and reap profits. The decision aligns with concerns about declining fundamentals, like terminating the CMV program, which could impact the company's future prospects and pipeline.
• Today's bearish movement in Moderna’s stock seems to stem from profit-taking post a recent rally, investor focus on key developments and funding, and uncertainties about the company’s strategic path amidst evolving market trends.

04.11.2025 - MRNA Stock was up 5.2%

• Moderna's stock has surpassed its 20-day moving average, indicating a short-term bullish trend that has caught traders' attention.
• Institutional activity surrounding Moderna has been a mix, with one entity reducing its stake significantly as another acquired a substantial number of shares.
• Analyst opinions on Moderna vary, with some recommending a "Hold" position, but the overall sentiment is positive due to strong earnings estimates.
• The increase in Moderna's stock price could be due to technical strength from crossing the moving average and favorable fundamental factors like earnings outlook, despite varying institutional investor actions.